GenCore version 5.1.4_p5_4578

OM nucleic - nucleic search, using sw model

Run on: March 10, 2003, 21:31:17 ; Search time 156.822 Seconds
(without alignments)
488.248 Million cell updates/sec

Title: US-09-913-524-33
Perfect score: 34
Sequence: 1 aggcctccggaggaaccgnctgcccatgccaact 34

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 1125999159 residues

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_101002:*
1: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA2001A.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA2001B.DAT:*
24: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	33	97.1	405	22	AAF84904	Nucleotide sequenc
	2	33	97.1	1134	7	AAN60428	Sequence encoding
	3	33	97.1	1237	8	AAN70314	Sequence encoding
	4	33	97.1	1338	9	AAN80040	Sequence encoding
c	5	33	97.1	3422	22	AAL03358	Human reproductive
c	6	33	97.1	3422	22	AAL03360	Human reproductive
c	7	33	97.1	3422	22	AAS28909	Human immunoglobul
	8	33	97.1	3422	22	AAS28911	Human immunoglobul
	9	25	73.5	1182	7	AAN60426	Sequence encoding
	10	23.4	68.8	1343	8	AAN70310	Sequence encoding
	11	20.8	61.2	5145	22	AAD06014	Human neuronal apo
	12	19.8	58.2	5172	23	ABL12657	Drosophila melanog
c	13	19.8	58.2	6410	23	ABL12656	Drosophila melanog
	14	19.6	57.6	1500	17	AAT06947	C-promoter binding
	15	19.6	57.6	1580	20	AAX39671	Renal cancer assoc
	16	19.6	57.6	1580	22	AAD11117	Human small cell l
	17	19.4	57.1	1087	22	AAH14269	Human cDNA sequenc
	18	19.4	57.1	1125	21	AAF16239	Human prostate can
	19	19.4	57.1	1183	21	AAZ98235	Human signal pepti
	20	19.4	57.1	1279	23	ABL04895	Drosophila melanog
	21	19.4	57.1	2297	22	AAH98586	Human EST-derived
	22	19.4	57.1	3210	23	ABL12861	Drosophila melanog
	23	19.4	57.1	3333	23	ABL04894	Drosophila melanog
	24	19.4	57.1	4219	23	ABL04902	Drosophila melanog
c	25	19.4	57.1	5981	23	ABL12860	Drosophila melanog
c	26	19.4	57.1	6109	23	AAH78667	Murine Col5a3 cDNA
	27	19.2	56.5	1812	22	AAD08562	Human partial card
	28	19.2	56.5	2127	19	AAV23246	Human adenylylcycl
	29	19.2	56.5	3192	22	AAS21281	Human cDNA sequenc
	30	19.2	56.5	3549	22	AAD08563	Human cardiac aden
	31	19.2	56.5	3552	22	AAD08567	Human cardiac aden
	32	19.2	56.5	4046	14	AAQ42525	Cardiac adenylyl c
	33	19.2	56.5	4131	21	AAA53923	Type VI adenylyl c
	34	19.2	56.5	4942	20	AAX00461	Human type VI aden
c	35	19.2	56.5	32082	22	AAL06991	Human reproductive
	36	19.2	56.5	45546	20	AAX23520	Human kidney amino
	37	19	55.9	613	19	AAV15304	Breast cancer-asso
	38	19	55.9	613	22	AAH25901	Human breast cance
	39	19	55.9	903	22	AAH81747	Human differential
	40	19	55.9	903	22	AAH25902	Human breast cance
c	41	19	55.9	1123	22	AA189533	Human polynucleoti
	42	19	55.9	3205	23	ABL15045	Drosophila melanog
c	43	19	55.9	4063	22	AAK70341	Human immune/haema
	44	19	55.9	4063	22	AAK82280	Human immune/haema
c	45	19	55.9	4935	23	ABL15050	Drosophila melanog

ALIGNMENTS

RESULT 1
AAF84904
ID AAF84904 standard; DNA; 405 BP.
XX
AC AAF84904;
XX
DT 09-JUL-2001 (first entry)
XX
DE Nucleotide sequence of an alphaC fragment of human inhibin.
XX
KW AlphaC portion; inhibin; alpha-subunit; glycoprotein;
KW follicle stimulating hormone; FSH; cancer; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 1..405
FT /*tag= a
FT /product= "alphaC fragment of human inhibin"
XX
PN WO200129079-A1.
XX
PD 26-APR-2001.
XX
PF 18-OCT-2000; 2000WO-AU01258.
XX
PR 18-OCT-1999; 99AU-0003485.
PR 03-AUG-2000; 2000AU-0009162.
XX
PA (PRIN-) PRINCE HENRY'S INST MEDICAL RES.
PA (GROO/) GROOME N P.
XX

```
PI   Groome NP,  Milne-Robertson DM,  Stanton PG,  Cahir NF;
XX
DR   WPI; 2001-308476/32.
DR   P-PSDB; AAB68139.
XX
PT   Immuno-interactive fragments of alpha-C portion of mammalian inhibin
PT   alpha-subunit used to, e.g. produce antigen-binding molecules for
PT   diagnosing cancer -
XX
PS   Example 2; Page 138-139; 159pp; English.
XX
CC   The present sequence encodes an alphaC portion of a human inhibin
CC   alpha-subunit. Inhibin is a dimeric glycoprotein which is able to
CC   inhibit the secretion of follicle stimulating hormone (FSH) by the
CC   pituitary. Immuno-interactive fragments of the alphaC portion of inhibin
CC   alpha-subunit are used to raise antibodies. The antibodies are used to
CC   diagnose cancer of tissues in the ovary, uterus, breast, pituitary,
CC   testis, or prostate. The antibodies may be used in immunoassays such
CC   as radio-immunoassays, affinity chromatography in isolating a natural
CC   or recombinant mammalian inhibin, and for screening expression
CC   libraries for variant polypeptides.
XX
SQ   Sequence 405 BP; 68 A; 148 C; 96 G; 93 T; 0 other;

  Query Match             97.1%;  Score 33;  DB 22;  Length 405;
  Best Local Similarity   97.1%;  Pred. No. 0.00059;
  Matches   33;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1 AGGCCTCCGGAGGAACCGNCTGCCCATGCCAACT 34
           ||||||||||||||||||| ||||||||||||||
Db      55 AGGCCTCCGGAGGAACCGGCTGCCCATGCCAACT 88


RESULT 2
AAN60428
ID   AAN60428 standard; cDNA; 1134 BP.
XX
AC   AAN60428;
XX
DT   26-JUN-1991  (first entry)
XX
DE   Sequence encoding human inhibin A subunit.
XX
KW   Hormone; inhibin agonist; antagonist; reproductive; gonad; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   CDS             8..190
FT                   /*tag=  a
FT   mat_peptide     191..1108
FT                   /*tag=  b
XX
PN   WO8606076-A.
XX
PD   23-OCT-1986.
XX
PF   14-APR-1986;   86WO-AU00097.
XX
PR   20-DEC-1985;   85AU-0003961.
PR   18-APR-1985;   85AU-0000194.
PR   06-SEP-1985;   85AU-0002320.
PR   29-OCT-1985;   85AU-0003157.
PR   19-DEC-1985;   85AU-0003960.
PR   01-JAN-1986;   86AU-0059039.
PR   02-APR-1987;   87AU-0071015.
PR   05-MAY-1986;   86CN-0103459.
XX
PA   (BIOT-) BIOTECHN AUSTR PTY.
PA   (MONU ) MONASH UNIV.
PA   (HENR-) PRICE HENRY'S HOSPITAL.
PA   (SVIN-) ST VINCENTS'S INST MED RE.
XX
PI   Forage R,  Stewart A,  Robertson D,  Dekretser DM;
XX
DR   WPI; 1986-291647/44.
DR   P-PSDB; AAP60519.
XX
PT   New polynucleotide sequences and recombinant DNA - encoding
PT   inhibin and synthetic peptides useful for affecting gonadal
PT   function
XX
PS   Claim 8; Fig 7; 71pp; English.
XX
CC   DNA encoding inhibin and inhibin or part, analogues, homologues or
CC   precursors thereof when produced by recombinant techniques are also
CC   claimed, as well as pharmaceutical compositions thereof. These may
CC   be used as an inhibin agonist, antagonist or for eliciting an
CC   antigenic response to affect gonadal function or reproductive
CC   physiology.
XX
SQ   Sequence 1134 BP; 182 A; 400 C; 322 G; 230 T; 0 other;

  Query Match             97.1%;  Score 33;  DB 7;  Length 1134;
  Best Local Similarity   97.1%;  Pred. No. 0.00064;
  Matches   33;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1 AGGCCTCCGGAGGAACCGNCTGCCCATGCCAACT 34
           ||||||||||||||||||| ||||||||||||||
Db     758 AGGCCTCCGGAGGAACCGGCTGCCCATGCCAACT 791


RESULT 3
AAN70314
ID   AAN70314 standard; cDNA; 1237 BP.
XX
AC   AAN70314;
XX
DT   09-APR-1991  (first entry)
XX
DE   Sequence encoding human inhibin alpha-chain precursor.
XX
KW   Fertility control; contraception; hormone; spermatogenesis; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   CDS             3..50
FT                   /*tag=  a
FT                   /product=signal sequence
FT   CDS             51..653
FT                   /*tag=  b
FT                   /product=pro region
FT   mat_peptide     654..1058
FT                   /*tag=  c
FT   poly_A signal   1216..1221
FT                   /*tag=  d
XX
PN   EP222491-A.
XX
PD   20-MAY-1987.
XX
PF   02-OCT-1986;   86EP-0307586.
XX
PR   12-SEP-1986;   86US-0906729.
PR   03-OCT-1985;   85US-0783910.
PR   10-FEB-1986;   86US-0827710.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Mason AJ,  Seeburg PH;
XX
DR   WPI; 1987-137512/20.
DR   P-PSDB; AAP70202.
XX
PT   Recombinant human or porcine inhibin or activin - used for
```

```
PT   modulating clinical condition or reproductive physiology of
PT   animals.
XX
PS   Disclosure; Fig 6A; 48pp; English.
XX
CC   A compsn. comprising human or porcine inhibin which is completely
CC   free of unidentified or porcine proteins is claimed.  Also claimed
CC   are non chromosomal DNA encoding inhibin-alpha or an inhibin-beta
CC   chain.  Sequencing of inhibin-encoding cDNA has led to the
CC   identification of prodomain regions located N-terminal to the
CC   mature inhibin chains that represent coordinately expressed
CC   biologically active polypeptides.  The prodomain regions or
CC   prodomain immunogens are useful in monitoring preproinhibin
CC   processing in transformant cell culture or in experiments directed
CC   at modulating the clinical condt. or reproductive physiology of
CC   animals.
XX
SQ   Sequence 1237 BP; 210 A; 431 C; 346 G; 250 T; 0 other;

  Query Match             97.1%;  Score 33;  DB 8;  Length 1237;
  Best Local Similarity   97.1%;  Pred. No. 0.00064;
  Matches   33;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1 AGGCCTCCGGAGGAACCGNCTGCCCATGCCAACT 34
           ||||||||||||||||||| ||||||||||||||
Db     708 AGGCCTCCGGAGGAACCGGCTGCCCATGCCAACT 741


RESULT 4
AAN80040
ID   AAN80040 standard; DNA; 1338 BP.
XX
AC   AAN80040;
XX
DT   28-JAN-1993  (first entry)
XX
DE   Sequence encoding the 18K alpha-chain of a protein exhibiting
DE   inhibin activity and its N-terminal sequence.
XX
KW   Fertility control; inhibin; follicle stimulating hormone; inhibitor;
KW   gonadotropin; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   CDS             145..840
FT                   /*tag= a
FT                   /product= N-terminal sequence
FT   CDS             841..1245
FT                   /*tag= b
FT                   /product= 18 K chain
FT                   /note= "claimed"
XX
PN   US4737578-A.
XX
PD   12-APR-1988.
XX
PF   07-APR-1986;   86US-0848924.
XX
PR   07-APR-1986;   86US-0848924.
PR   10-FEB-1986;   86US-0828435.
XX
PA   (SALK ) SALK INST FOR BIOL STUD.
XX
PI   Evans RM,  Rosenfeld MG,  Cerelli G,  Mayo KE,  Spiess J;
PI   Rivier JEF,  Vale WW;
XX
DR   WPI; 1988-119128/17.
DR   P-PSDB; AAP83167.
XX
PT   New proteins with inhibin activity - esp. useful for controlling
PT   fertility in males
XX
PS   Disclosure; Table 1, page 6-7; 6pp; English.
XX
CC   The inventors claim 2 proteins - A and B - each of which has a
CC   molecular weight of about 32K and is comprised of an alpha (18K) and
CC   a beta (14K) chain of human inhibin.  The alpha chain is AAP80018.
CC   The beta chain is either AAP80019 or AAP80020.  Proteins A and B are
CC   useful for regulating fertility of mammals.  Each 32K protein
CC   exhibits inhibin activity in basal secretion of FHS but not
CC   inhibiting basal secretion of luteinizing hormone (LH).
XX
SQ   Sequence 1338 BP; 232 A; 433 C; 417 G; 256 T; 0 other;

  Query Match             97.1%;  Score 33;  DB 9;  Length 1338;
  Best Local Similarity   97.1%;  Pred. No. 0.00064;
  Matches   33;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1 AGGCCTCCGGAGGAACCGNCTGCCCATGCCAACT 34
           ||||||||||||||||||| ||||||||||||||
Db     895 AGGCCTCCGGAGGAACCGGCTGCCCATGCCAACT 928


RESULT 5
AAL03358/c
ID   AAL03358 standard; DNA; 3422 BP.
XX
AC   AAL03358;
XX
DT   21-NOV-2001  (first entry)
XX
DE   Human reproductive system related antigen DNA SEQ ID NO: 6046.
XX
KW   Human; reproductive system related antigen; reproductive system disorder;
KW   cancer; gene therapy; ds.
XX
OS   Homo sapiens.
XX
PN   WO200155320-A2.
XX
PD   02-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US01339.
XX
PR   31-JAN-2000; 2000US-0179065.
PR   04-FEB-2000; 2000US-0180628.
PR   24-FEB-2000; 2000US-0184664.
PR   02-MAR-2000; 2000US-0186350.
PR   16-MAR-2000; 2000US-0189874.
PR   17-MAR-2000; 2000US-0190076.
PR   18-APR-2000; 2000US-0198123.
PR   19-MAY-2000; 2000US-0205515.
PR   07-JUN-2000; 2000US-0209467.
PR   28-JUN-2000; 2000US-0214886.
PR   30-JUN-2000; 2000US-0215135.
PR   07-JUL-2000; 2000US-0216647.
PR   07-JUL-2000; 2000US-0216880.
PR   11-JUL-2000; 2000US-0217487.
PR   11-JUL-2000; 2000US-0217496.
PR   14-JUL-2000; 2000US-0218290.
PR   26-JUL-2000; 2000US-0220963.
PR   26-JUL-2000; 2000US-0220964.
PR   14-AUG-2000; 2000US-0224518.
PR   14-AUG-2000; 2000US-0224519.
PR   14-AUG-2000; 2000US-0225213.
PR   14-AUG-2000; 2000US-0225214.
PR   14-AUG-2000; 2000US-0225266.
PR   14-AUG-2000; 2000US-0225267.
PR   14-AUG-2000; 2000US-0225268.
PR   14-AUG-2000; 2000US-0225270.
PR   14-AUG-2000; 2000US-0225447.
PR   14-AUG-2000; 2000US-0225757.
PR   14-AUG-2000; 2000US-0225758.
PR   14-AUG-2000; 2000US-0225759.
PR   18-AUG-2000; 2000US-0226279.
```

PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-465570/50.
XX
PT Isolated nucleic acid molecule encoding a reproductive system antigen
PT is used in preventing, treating or ameliorating a medical condition -
XX
PS Disclosure; SEQ ID NO 6046; 1297pp + Sequence Listing; English.
XX
CC The present invention provides the protein and coding sequences of a
CC number of human reproductive system related antigens. These can be used
CC in the prevention and treatment of reproductive system disorders,
CC including cancer. The present sequence is a genomic sequence encoding a
CC protein of the invention.
XX
SQ Sequence 3422 BP; 806 A; 898 C; 962 G; 756 T; 0 other;

Query Match 97.1%; Score 33; DB 22; Length 3422;
Best Local Similarity 97.1%; Pred. No. 0.00069;
Matches 33; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 AGGCCTCCGGAGGAACCGNCTGCCCATGCCAACT 34
||||||||||||||||| ||||||||||||||||
Db 538 AGGCCTCCGGAGGAACCGGCTGCCCATGCCAACT 505

RESULT 6
AAL03360/c
ID AAL03360 standard; DNA; 3422 BP.
XX
AC AAL03360;
XX
DT 21-NOV-2001 (first entry)
XX
DE Human reproductive system related antigen DNA SEQ ID NO: 6048.
XX
KW Human; reproductive system related antigen; reproductive system disorder;
KW cancer; gene therapy; ds.

XX
OS Homo sapiens.
XX
PN W0200155320-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01339.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX

```
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Barash SC,  Ruben SM;
XX
DR   WPI; 2001-465570/50.
XX
PT   Isolated nucleic acid molecule encoding a reproductive system antigen
PT   is used in preventing, treating or ameliorating a medical condition -
XX
PS   Disclosure; SEQ ID NO 6048; 1297pp + Sequence Listing; English.
XX
CC   The present invention provides the protein and coding sequences of a
CC   number of human reproductive system related antigens. These can be used
CC   in the prevention and treatment of reproductive system disorders,
CC   including cancer. The present sequence is a genomic sequence encoding a
CC   protein of the invention.
XX
SQ   Sequence 3422 BP; 806 A; 898 C; 962 G; 756 T; 0 other;

  Query Match             97.1%;  Score 33;  DB 22;  Length 3422;
  Best Local Similarity   97.1%;  Pred. No. 0.00069;
  Matches   33;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1 AGGCCTCCGGAGGAACCGNCTGCCCATGCCAACT 34
           |||||||||||||||||| ||||||||||||||||
Db     538 AGGCCTCCGGAGGAACCGGCTGCCCATGCCAACT 505


RESULT 7
AAS28909/c
ID   AAS28909 standard; DNA; 3422 BP.
XX
AC   AAS28909;
XX
DT   07-NOV-2001  (first entry)
XX
DE   Human immunoglobulin encoding genomic DNA SEQ ID No 271.
XX
KW   Immunoglobulin; signal transduction pathway protein; cancer; ds;
KW   antisense therapy; gene therapy; neurological disorder; renal disorder;
KW   cardiovascular disorder; gastrointestinal disorder; pulmonary disorder;
KW   reproductive disorder; immune system disorder; proliferative disorder;
KW   muscular disorder.
XX
OS   Homo sapiens.
XX
PN   WO200155315-A2.
XX
PD   02-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US01326.
XX
PR   31-JAN-2000; 2000US-0179065.
PR   04-FEB-2000; 2000US-0180628.
PR   24-FEB-2000; 2000US-0184664.
PR   02-MAR-2000; 2000US-0186350.
PR   16-MAR-2000; 2000US-0189874.
PR   17-MAR-2000; 2000US-0190076.
PR   18-APR-2000; 2000US-0198123.
PR   19-MAY-2000; 2000US-0205515.
PR   07-JUN-2000; 2000US-0209467.
PR   28-JUN-2000; 2000US-0214886.
PR   30-JUN-2000; 2000US-0215135.
PR   07-JUL-2000; 2000US-0216647.
PR   07-JUL-2000; 2000US-0216880.
PR   11-JUL-2000; 2000US-0217487.
PR   11-JUL-2000; 2000US-0217496.
PR   14-JUL-2000; 2000US-0218290.
PR   26-JUL-2000; 2000US-0220963.
PR   26-JUL-2000; 2000US-0220964.
PR   14-AUG-2000; 2000US-0224518.
PR   14-AUG-2000; 2000US-0224519.
PR   14-AUG-2000; 2000US-0225213.
PR   14-AUG-2000; 2000US-0225214.
PR   14-AUG-2000; 2000US-0225266.
PR   14-AUG-2000; 2000US-0225267.
PR   14-AUG-2000; 2000US-0225268.
PR   14-AUG-2000; 2000US-0225270.
PR   14-AUG-2000; 2000US-0225447.
PR   14-AUG-2000; 2000US-0225757.
PR   14-AUG-2000; 2000US-0225758.
PR   14-AUG-2000; 2000US-0225759.
PR   18-AUG-2000; 2000US-0226279.
PR   22-AUG-2000; 2000US-0226681.
PR   22-AUG-2000; 2000US-0226868.
PR   22-AUG-2000; 2000US-0227182.
PR   23-AUG-2000; 2000US-0227009.
PR   30-AUG-2000; 2000US-0228924.
PR   01-SEP-2000; 2000US-0229287.
PR   01-SEP-2000; 2000US-0229343.
PR   01-SEP-2000; 2000US-0229344.
PR   01-SEP-2000; 2000US-0229345.
PR   05-SEP-2000; 2000US-0229509.
PR   05-SEP-2000; 2000US-0229513.
PR   06-SEP-2000; 2000US-0230437.
PR   06-SEP-2000; 2000US-0230438.
PR   08-SEP-2000; 2000US-0231242.
PR   08-SEP-2000; 2000US-0231243.
PR   08-SEP-2000; 2000US-0231244.
PR   08-SEP-2000; 2000US-0231413.
PR   08-SEP-2000; 2000US-0231414.
PR   08-SEP-2000; 2000US-0232080.
PR   08-SEP-2000; 2000US-0232081.
PR   12-SEP-2000; 2000US-0231968.
PR   14-SEP-2000; 2000US-0232397.
PR   14-SEP-2000; 2000US-0232398.
PR   14-SEP-2000; 2000US-0232399.
PR   14-SEP-2000; 2000US-0232400.
PR   14-SEP-2000; 2000US-0232401.
PR   14-SEP-2000; 2000US-0233063.
PR   14-SEP-2000; 2000US-0233064.
PR   14-SEP-2000; 2000US-0233065.
PR   21-SEP-2000; 2000US-0234223.
PR   21-SEP-2000; 2000US-0234274.
PR   25-SEP-2000; 2000US-0234997.
PR   25-SEP-2000; 2000US-0234998.
PR   26-SEP-2000; 2000US-0235484.
PR   27-SEP-2000; 2000US-0235834.
PR   27-SEP-2000; 2000US-0235836.
PR   29-SEP-2000; 2000US-0236327.
PR   29-SEP-2000; 2000US-0236367.
PR   29-SEP-2000; 2000US-0236368.
PR   29-SEP-2000; 2000US-0236369.
PR   29-SEP-2000; 2000US-0236370.
PR   02-OCT-2000; 2000US-0236802.
PR   02-OCT-2000; 2000US-0237037.
PR   02-OCT-2000; 2000US-0237038.
PR   02-OCT-2000; 2000US-0237039.
PR   02-OCT-2000; 2000US-0237040.
PR   13-OCT-2000; 2000US-0239935.
PR   13-OCT-2000; 2000US-0239937.
PR   20-OCT-2000; 2000US-0240960.
PR   20-OCT-2000; 2000US-0241221.
PR   20-OCT-2000; 2000US-0241785.
PR   20-OCT-2000; 2000US-0241786.
PR   20-OCT-2000; 2000US-0241787.
PR   20-OCT-2000; 2000US-0241808.
PR   20-OCT-2000; 2000US-0241809.
PR   20-OCT-2000; 2000US-0241826.
PR   01-NOV-2000; 2000US-0244617.
PR   08-NOV-2000; 2000US-0246474.
PR   08-NOV-2000; 2000US-0246475.
PR   08-NOV-2000; 2000US-0246476.
PR   08-NOV-2000; 2000US-0246477.
PR   08-NOV-2000; 2000US-0246478.
PR   08-NOV-2000; 2000US-0246523.
```

```
PR   08-NOV-2000; 2000US-0246524.
PR   08-NOV-2000; 2000US-0246525.
PR   08-NOV-2000; 2000US-0246526.
PR   08-NOV-2000; 2000US-0246527.
PR   08-NOV-2000; 2000US-0246528.
PR   08-NOV-2000; 2000US-0246532.
PR   08-NOV-2000; 2000US-0246609.
PR   08-NOV-2000; 2000US-0246610.
PR   08-NOV-2000; 2000US-0246611.
PR   08-NOV-2000; 2000US-0246613.
PR   17-NOV-2000; 2000US-0249207.
PR   17-NOV-2000; 2000US-0249208.
PR   17-NOV-2000; 2000US-0249209.
PR   17-NOV-2000; 2000US-0249210.
PR   17-NOV-2000; 2000US-0249211.
PR   17-NOV-2000; 2000US-0249212.
PR   17-NOV-2000; 2000US-0249213.
PR   17-NOV-2000; 2000US-0249214.
PR   17-NOV-2000; 2000US-0249215.
PR   17-NOV-2000; 2000US-0249216.
PR   17-NOV-2000; 2000US-0249217.
PR   17-NOV-2000; 2000US-0249218.
PR   17-NOV-2000; 2000US-0249244.
PR   17-NOV-2000; 2000US-0249245.
PR   17-NOV-2000; 2000US-0249264.
PR   17-NOV-2000; 2000US-0249265.
PR   17-NOV-2000; 2000US-0249297.
PR   17-NOV-2000; 2000US-0249299.
PR   17-NOV-2000; 2000US-0249300.
PR   01-DEC-2000; 2000US-0250160.
PR   01-DEC-2000; 2000US-0250391.
PR   05-DEC-2000; 2000US-0251030.
PR   05-DEC-2000; 2000US-0251988.
PR   05-DEC-2000; 2000US-0256719.
PR   06-DEC-2000; 2000US-0251479.
PR   08-DEC-2000; 2000US-0251856.
PR   08-DEC-2000; 2000US-0251868.
PR   08-DEC-2000; 2000US-0251869.
PR   08-DEC-2000; 2000US-0251989.
PR   08-DEC-2000; 2000US-0251990.
PR   11-DEC-2000; 2000US-0254097.
PR   05-JAN-2001; 2001US-0259678.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Barash SC,  Ruben SM;
XX
DR   WPI; 2001-457725/49.
XX
PT   Isolated novel immunoglobulin polypeptide for monitoring the presence
PT   and progression of diseases and for diagnosis -
XX
PS   Claim 1; SEQ ID No 271; 551pp; English.
XX
CC   Sequences AAS28878-AAS28926 represent genomic DNA molecules which encode
CC   the immunoglobulin polypeptides of the invention. The polynucleotides and
CC   polypeptides can be used to diagnose a pathological condition or a
CC   susceptibility to a pathological condition in a subject by determining
CC   the presence or absence of a mutation in a DNA sequence or determining
CC   the presence or amount of expression of the protein. Alternatively the
CC   identification of a binding partner to a sequence allows determination of
CC   changes in protein activity. The sequences can be used as research tools
CC   for receptors or other signal transduction pathway proteins that interact
CC   with the polypeptides of the invention and can be used to treat, prevent
CC   or diagnose various types of disorders such as neurological disorders,
CC   cardiovascular disorders, gastrointestinal disorders, reproductive
CC   disorders, immune system disorders, renal disorders, muscular disorders,
CC   pulmonary disorders, proliferative disorders and cancer.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 3422 BP; 806 A; 898 C; 962 G; 756 T; 0 other;
```

```
  Query Match             97.1%;  Score 33;  DB 22;  Length 3422;
  Best Local Similarity   97.1%;  Pred. No. 0.00069;
  Matches   33;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1 AGGCCTCCGGAGGAACCGNCTGCCCATGCCAACT 34
           ||||||||||||||||||| ||||||||||||||
Db     538 AGGCCTCCGGAGGAACCGGCTGCCCATGCCAACT 505


RESULT 8
AAS28911
ID   AAS28911 standard; DNA; 3422 BP.
XX
AC   AAS28911;
XX
DT   07-NOV-2001  (first entry)
XX
DE   Human immunoglobulin encoding genomic DNA SEQ ID No 273.
XX
KW   Immunoglobulin; signal transduction pathway protein; cancer; ds;
KW   antisense therapy; gene therapy; neurological disorder; renal disorder;
KW   cardiovascular disorder; gastrointestinal disorder; pulmonary disorder;
KW   reproductive disorder; immune system disorder; proliferative disorder;
KW   muscular disorder.
XX
OS   Homo sapiens.
XX
PN   WO200155315-A2.
XX
PD   02-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US01326.
XX
PR   31-JAN-2000; 2000US-0179065.
PR   04-FEB-2000; 2000US-0180628.
PR   24-FEB-2000; 2000US-0184664.
PR   02-MAR-2000; 2000US-0186350.
PR   16-MAR-2000; 2000US-0189874.
PR   17-MAR-2000; 2000US-0190076.
PR   18-APR-2000; 2000US-0198123.
PR   19-MAY-2000; 2000US-0205515.
PR   07-JUN-2000; 2000US-0209467.
PR   28-JUN-2000; 2000US-0214886.
PR   30-JUN-2000; 2000US-0215135.
PR   07-JUL-2000; 2000US-0216647.
PR   07-JUL-2000; 2000US-0216880.
PR   11-JUL-2000; 2000US-0217487.
PR   11-JUL-2000; 2000US-0217496.
PR   14-JUL-2000; 2000US-0218290.
PR   26-JUL-2000; 2000US-0220963.
PR   26-JUL-2000; 2000US-0220964.
PR   14-AUG-2000; 2000US-0224518.
PR   14-AUG-2000; 2000US-0224519.
PR   14-AUG-2000; 2000US-0225213.
PR   14-AUG-2000; 2000US-0225214.
PR   14-AUG-2000; 2000US-0225266.
PR   14-AUG-2000; 2000US-0225267.
PR   14-AUG-2000; 2000US-0225268.
PR   14-AUG-2000; 2000US-0225270.
PR   14-AUG-2000; 2000US-0225447.
PR   14-AUG-2000; 2000US-0225757.
PR   14-AUG-2000; 2000US-0225758.
PR   14-AUG-2000; 2000US-0225759.
PR   18-AUG-2000; 2000US-0226279.
PR   22-AUG-2000; 2000US-0226681.
PR   22-AUG-2000; 2000US-0226868.
PR   22-AUG-2000; 2000US-0227182.
PR   23-AUG-2000; 2000US-0227009.
PR   30-AUG-2000; 2000US-0228924.
PR   01-SEP-2000; 2000US-0229287.
PR   01-SEP-2000; 2000US-0229343.
PR   01-SEP-2000; 2000US-0229344.
```

PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-457725/49.
XX
PT Isolated novel immunoglobulin polypeptide for monitoring the presence
PT and progression of diseases and for diagnosis -
XX
PS Claim 1; SEQ ID No 273; 551pp; English.
XX
CC Sequences AAS28878-AAS28926 represent genomic DNA molecules which encode
CC the immunoglobulin polypeptides of the invention. The polynucleotides and
CC polypeptides can be used to diagnose a pathological condition or a
CC susceptibility to a pathological condition in a subject by determining
CC the presence or absence of a mutation in a DNA sequence or determining
CC the presence or amount of expression of the protein. Alternatively the
CC identification of a binding partner to a sequence allows determination of
CC changes in protein activity. The sequences can be used as research tools
CC for receptors or other signal transduction pathway proteins that interact
CC with the polypeptides of the invention and can be used to treat, prevent
CC or diagnose various types of disorders such as neurological disorders,
CC cardiovascular disorders, gastrointestinal disorders, reproductive
CC disorders, immune system disorders, renal disorders, muscular disorders,
CC pulmonary disorders, proliferative disorders and cancer.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 3422 BP; 756 A; 962 C; 898 G; 806 T; 0 other;

Query Match 97.1%; Score 33; DB 22; Length 3422;
Best Local Similarity 97.1%; Pred. No. 0.00069;
Matches 33; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 AGGCCTCCGGAGGAACCGNCTGCCCATGCCAACT 34
||||||||||||||||||| ||||||||||||||||
Db 2885 AGGCCTCCGGAGGAACCGGCTGCCCATGCCAACT 2918

RESULT 9
AAN60426
ID AAN60426 standard; cDNA; 1182 BP.
XX
AC AAN60426;
XX
DT 26-JUN-1991 (first entry)
XX

```
DE   Sequence encoding bovine inhibin A subunit.
XX
KW   Hormone; inhibin agonist; antagonist; reproductive; gonad; ss.
XX
OS   Bos taurus.
XX
FH   Key             Location/Qualifiers
FT   CDS             61..240
FT                   /*tag= a
FT   mat_peptide     241..1143
FT                   /*tag= b
XX
PN   WO8606076-A.
XX
PD   23-OCT-1986.
XX
PF   14-APR-1986;    86WO-AU00097.
XX
PR   20-DEC-1985;    85AU-0003961.
PR   18-APR-1985;    85AU-0000194.
PR   06-SEP-1985;    85AU-0002320.
PR   29-OCT-1985;    85AU-0003157.
PR   19-DEC-1985;    85AU-0003960.
PR   01-JAN-1986;    86AU-0059039.
PR   02-APR-1987;    87AU-0071015.
PR   05-MAY-1986;    86CN-0103459.
XX
PA   (BIOT-) BIOTECHN AUSTR PTY.
PA   (MONU ) MONASH UNIV.
PA   (HENR-) PRICE HENRY'S HOSPITAL.
PA   (SVIN-) ST VINCENTS'S INST MED RE.
XX
PI   Forage R,  Stewart A,  Robertson D,  Dekretser DM;
XX
DR   WPI; 1986-291647/44.
DR   P-PSDB; AAP60517.
XX
PT   New polynucleotide sequences and recombinant DNA - encoding
PT   inhibin and synthetic peptides useful for affecting gonadal
PT   function
XX
PS   Claim 8; Fig 5; 71pp; English.
XX
CC   DNA encoding inhibin and inhibin or part, analogues, homologues or
CC   precursors thereof when produced by recombinant techniques are also
CC   claimed, as well as pharmaceutical compositions thereof. These may
CC   be used as an inhibin agonist, antagonist or for eliciting an
CC   antigenic response to affect gonadal function or reproductive
CC   physiology.
XX
SQ   Sequence 1182 BP; 173 A; 414 C; 363 G; 232 T; 0 other;

  Query Match             73.5%;  Score 25;  DB 7;  Length 1182;
  Best Local Similarity   82.4%;  Pred. No. 1;
  Matches   28;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1 AGGCCTCCGGAGGAACCGNCTGCCCATGCCAACT 34
           ||||||| ||||| || | ||||||||| |||
Db     793 AGGCCTCCAGAGGAGCCCGCCGCCCATGCCGACT 826


RESULT 10
AAN70310
ID   AAN70310 standard; cDNA; 1343 BP.
XX
AC   AAN70310;
XX
DT   09-APR-1991  (first entry)
XX
DE   Sequence encoding porcine inhibin alpha-chain precursor.
XX
KW   Fertility control; contraception; hormone; spermatogenesis; ss.
XX
OS   Sus scrofa domestica.
XX
FH   Key             Location/Qualifiers
FT   CDS             72..761
FT                   /*tag= a
FT                   /product=hydrophobic signal sequence a pro-region
FT   mat_peptide     762..1166
FT                   /*tag= b
FT   polyA_signal    1300..1305
FT                   /*tag= c
XX
PN   EP222491-A.
XX
PD   20-MAY-1987.
XX
PF   02-OCT-1986;    86EP-0307586.
XX
PR   12-SEP-1986;    86US-0906729.
PR   03-OCT-1985;    85US-0783910.
PR   10-FEB-1986;    86US-0827710.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Mason AJ,  Seeburg PH;
XX
DR   WPI; 1987-137512/20.
DR   P-PSDB; AAP70199.
XX
PT   Recombinant human or porcine inhibin or activin - used for
PT   modulating clinical condition or reproductive physiology of
PT   animals.
XX
PS   Disclosure; Fig 1B; 48pp; English.
XX
CC   A compsn. comprising human or porcine inhibin which is completely
CC   free of unidentified or porcine proteins is claimed.  Also claimed
CC   are non chromosomal DNA encoding inhibin-alpha or an inhibin-beta
CC   chain.  Sequencing of inhibin-encoding cDNA has led to the
CC   identification of prodomain regions located N-terminal to the
CC   mature inhibin chains that represent coordinately expressed
CC   biologically active polypeptides.  The prodomain regions or
CC   prodomain immunogens are useful in monitoring preproinhibin
CC   processing in transformant cell culture or in experiments directed
CC   at modulating the clinical condt. or reproductive physiology of
CC   animals.
XX
SQ   Sequence 1343 BP; 196 A; 472 C; 417    258 T; 0 other;

  Query Match             68.8%;  Score 23.1;  DB 8;  Length 1343;
  Best Local Similarity   79.4%;  Pred. No. 4.6;
  Matches   27;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1 AGGCCTCCGGAGGAACCGNCTGCCCATGCCAACT 34
           ||||| ||||||||||| ||| || ||| |||
Db     816 AGGCCCCCGGAGGAACCCGCCTGTGCACGCCGACT 849


RESULT 11
AAD06014
ID   AAD06014 standard; DNA; 5145 BP.
XX
AC   AAD06014;
XX
DT   31-JUL-2001  (first entry)
XX
DE   Human neuronal apoptosis regulated candidate (NARC) 25 DNA.
XX
KW   Human; neuronal apoptosis regulated candidate 25; NARC 25; cytostatic;
KW   chromosome mapping; gene therapy; antisense therapy; lung disorder;
KW   central nervous system disorder; apoptosis; spleen disorder; angina;
KW   tuberculosis; Goodpasture's syndrome; liver disorder; jaundice;
KW   infectious disorder; brain disorder; cerebral oedema; gonorrhoea;
KW   heart disorder; kidney disorder; glomerulonephritis; testes; virucide;
```

```
KW   epididymis disorder; skeletal muscle disorder; pancreatic disorder;
KW   diabetes; cytoprotectant; immunostimulant; tumour;
KW   antiinflammatory; antimicrobial; neuroprotective; gynaecological; ds.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   CDS             113..1393
FT                   /*tag= a
FT                   /product= "Human NARC 25 protein"
XX
PN   WO200131007-A2.
XX
PD   03-MAY-2001.
XX
PF   20-OCT-2000; 2000WO-US29132.
XX
PR   22-OCT-1999;   99US-0161188.
XX
PA   (MILL-) MILLENNIUM PHARM INC.
XX
PI   Chiang LW;
XX
DR   WPI; 2001-308641/32.
DR   P-PSDB; AAE02056.
XX
PT   Rat brain polypeptides, nucleic acids and antibodies, useful for
PT   diagnosis and treatment of central nervous system disorders and
PT   disorders associated with aberrant apoptosis -
XX
PS   Claim 1; Page 158-160; 161pp; English.
XX
CC   The invention relates to human homologues of neuronal apoptosis
CC   regulated candidate (NARC) nucleic acid molecules and proteins derived
CC   from rat brain and programmed cell death libraries. The nucleic acids
CC   of the invention are useful for assaying the presence of a nucleic acid
CC   molecule and for chromosome mapping. They are also used in gene therapy
CC   and antisense therapy. The NARC sequences are useful for
CC   treating central nervous system disorders and disorders involving
CC   aberrant apoptosis, for inducing an immune response and for isolating
CC   binding partners. Diseases treated include spleen disorders (e.g.
CC   tuberculosis and congestive splenomegaly), lung disorders (e.g. adult
CC   respiratory distress syndrome, Goodpasture's syndrome and bronchial
CC   asthma), liver disorders (e.g. jaundice and hepatic failure), infectious
CC   disorders (e.g. viral hepatitis), brain disorders (e.g. cerebral oedema,
CC   hypertensive encephalopathy and hydrocephalus), heart disorders (e.g.
CC   heart failure, angina and myocardial infarction), kidney disorders (e.g.
CC   cysts and glomerulonephritis), testes and epididymis disorders (e.g.
CC   gonorrhoea and syphilis), skeletal muscle disorders (e.g. tumours) and
CC   pancreatic disorders (e.g. pancreatitis and diabetes).
CC   The present sequence is human neuronal apoptosis regulated candidate
CC   (NARC) 25 DNA.
XX
SQ   Sequence 5145 BP; 1327 A; 1232 C; 1232 G; 1354 T; 0 other;

  Query Match             61.2%;  Score 20.8;  DB 22;  Length 5145;
  Best Local Similarity   75.8%;  Pred. No. 57;
  Matches   25;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 AGGCCTCCGGAGGAACCGNCTGCCCATGCCAAC 33
           ||| || ||||||| ||  |||| | ||||| |
Db     419 AGGTCTACGGAGGACCCCACTGCACCTGCCAGC 451


RESULT 12
ABL12657
ID   ABL12657 standard; cDNA; 5172 BP.
XX
AC   ABL12657;
XX
DT   26-MAR-2002  (first entry)
XX
DE   Drosophila melanogaster expressed polynucleotide SEQ ID NO 32453.
XX
KW   Drosophila; developmental biology; cell signalling; insecticide;
KW   pharmaceutical; gene; ss.
XX
OS   Drosophila melanogaster.
XX
PN   WO200171042-A2.
XX
PD   27-SEP-2001.
XX
PF   23-MAR-2001; 2001WO-US09231.
XX
PR   23-MAR-2000; 2000US-191637P.
PR   11-JUL-2000; 2000US-0614150.
XX
PA   (PEKE ) PE CORP NY.
XX
PI   Venter JC,  Adams M,  Li PWD,  Myers EW;
XX
DR   WPI; 2001-656860/75.
DR   P-PSDB; ABB68554.
XX
PT   New isolated nucleic acid detection reagent for detecting 1000 or more
PT   genes from Drosophila and for elucidating cell signalling and cell-cell
PT   interactions -
XX
PS   Claim 1; SEQ ID NO 32453; 21pp + Sequence Listing; English.
XX
CC   The invention relates to an isolated nucleic acid detection reagent
CC   capable of detecting 1000 or more genes from Drosophila. The invention is
CC   useful in developmental biology and in elucidating cell signalling and
CC   cell-cell interactions in higher eukaryotes for the development of
CC   insecticides, therapeutics and pharmaceutical drugs. The invention
CC   discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
CC   sequences (ABL01840-ABL16175) and the encoded proteins
CC   (ABB57737-ABB72072).
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 5172 BP; 1286 A; 1567 C; 1489 G; 830 T; 0 other;

  Query Match             58.2%;  Score 19.8;  DB 23;  Length 5172;
  Best Local Similarity   75.0%;  Pred. No. 1.4e+02;
  Matches   24;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 AGGCCTCCGGAGGAACCGNCTGCCCATGCCAA 32
           | ||| |||| ||||||  |||||  |||||
Db    2977 AAGCCGCCGGTGGAACCCGCTGCCGCCGCCAA 3008


RESULT 13
ABL12656/c
ID   ABL12656 standard; cDNA; 6410 BP.
XX
AC   ABL12656;
XX
DT   26-MAR-2002  (first entry)
XX
DE   Drosophila melanogaster expressed polynucleotide SEQ ID NO 32450.
XX
KW   Drosophila; developmental biology; cell signalling; insecticide;
KW   pharmaceutical; gene; ss.
XX
OS   Drosophila melanogaster.
XX
PN   WO200171042-A2.
XX
PD   27-SEP-2001.
XX
PF   23-MAR-2001; 2001WO-US09231.
XX
PR   23-MAR-2000; 2000US-191637P.
```

```
PR   11-JUL-2000; 2000US-0614150.
XX
PA   (PEKE ) PE CORP NY.
XX
PI   Venter JC,  Adams M,  Li PWD,  Myers EW;
XX
DR   WPI; 2001-656860/75.
DR   P-PSDB; ABB68553.
XX
PT   New isolated nucleic acid detection reagent for detecting 1000 or more
PT   genes from Drosophila and for elucidating cell signalling and cell-cell
PT   interactions -
XX
PS   Claim 1; SEQ ID NO 32450; 21pp + Sequence Listing; English.
XX
CC   The invention relates to an isolated nucleic acid detection reagent
CC   capable of detecting 1000 or more genes from Drosophila. The invention is
CC   useful in developmental biology and in elucidating cell signalling and
CC   cell-cell interactions in higher eukaryotes for the development of
CC   insecticides, therapeutics and pharmaceutical drugs. The invention
CC   discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
CC   sequences (ABL01840-ABL16175) and the encoded proteins
CC   (ABB57737-ABB72072).
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 6410 BP; 1179 A; 1787 C; 1832 G; 1612 T; 0 other;

  Query Match             58.2%;  Score 19.8;  DB 23;  Length 6410;
  Best Local Similarity   75.0%;  Pred. No. 1.5e+02;
  Matches   24;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 AGGCCTCCGGAGGAACCGNCTGCCCATGCCAA 32
           | ||| |||| |||||| ||||| |||||
Db    3335 AAGCCGCCGGTGGAACCCGCTGCCGCCGCCAA 3304


RESULT 14
AAT06947
ID   AAT06947 standard; cDNA; 1500 BP.
XX
AC   AAT06947;
XX
DT   26-JUN-1996  (first entry)
XX
DE   C-promoter binding factor 1 coding sequence.
XX
KW   C-promoter binding factor 1; CBF1; transcription factor; TF; EBNA2;
KW   Epstein-Barr virus; CBF1-TF transcription complex; viral infection;
KW   bacterial infection; fungal infection; metabolic disease; inflammation;
KW   genetic disease; cell growth disfunction; regulatory disfunction;
KW   neoplasm; hypersensitivity; human; animal; plant; therapy; ds.
XX
OS   Synthetic.
XX
PN   WO9532307-A1.
XX
PD   30-NOV-1995.
XX
PF   17-MAY-1995;   95WO-US05966.
XX
PR   20-MAY-1994;   94US-0246977.
XX
PA   (TULA-) TULARIK INC.
XX
PI   Henkel T,  Peterson MG;
XX
DR   WPI; 1996-020599/02.
DR   P-PSDB; AAR86790.
XX
PT   Screening cpds. which disrupt complex formation between C-promoter
PT   binding factor and transcription factor - potentially useful for
PT   treating diseases involving the expression of a gene modulated by
PT   such complex formation
XX
PS   Claim 1; Page 22-24; 34pp; English.
XX
CC   This sequence represents the cDNA encoding C-promoter binding factor-1
CC   (CBF1). A partially purifed form of the protein encoded by this sequence
CC   is used in the method of the invention. The method is used for screening
CC   a chemical library for pharmacological agents. The protein is able to
CC   selectively bind to a transcription factor (TF) (such as Epstein-Barr
CC   virus EBNA2), and a test compound. The sample is incubated under
CC   conditions that allow the protein and the TF to bind. The presence or
CC   absence of binding of CBF1 and TF is then detected. Absence of binding
CC   indicates that the test compound disrupts CBF1-TF dependent gene
CC   expression. This method is also modified to include a labelled nucleic
CC   acid sequence containing the sequence GGGA in the incubation mixture.
CC   When the nucleic acid is used, the presence or absence of the binding of
CC   the CBF1-TF transcription complex to the nucleic acid sequence is
CC   detected. The test compounds identified are potentially useful for
CC   treating diseases associated with expression of a gene modulated by a
CC   CBF1-TF transcription complex. These include viral, bacterial or fungal
CC   infections, metabolic or genetic diseases and cell growth/regulatory
CC   disfunction (such as neoplasms, inflammation or hypersensitivity), in
CC   humans animals or plants.
XX
SQ   Sequence 1500 BP; 465 A; 319 C; 346 G; 370 T; 0 other;

  Query Match             57.6%;  Score 19.6;  DB 17;  Length 1500;
  Best Local Similarity   81.5%;  Pred. No. 1.6e+02;
  Matches   22;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       3 GCCTCCGGAGGAACCGNCTGCCCATGC 29
           |||  ||||||| ||| |||| |||||
Db      21 GCCCGCGGAGGAGCCGCCTGCGCATGC 47


RESULT 15
AAX39671
ID   AAX39671 standard; DNA; 1580 BP.
XX
AC   AAX39671;
XX
DT   02-JUL-1999  (first entry)
XX
DE   Renal cancer associated gene.
XX
KW   Cancer associated antigen; diagnosis; research; treatment; human;
KW   breast cancer; colon cancer; gastric cancer; renal cancer; lung cancer;
KW   prostate cancer; ss.
XX
OS   Homo sapiens.
XX
PN   WO9904265-A2.
XX
PD   28-JAN-1999.
XX
PF   15-JUL-1998;   98WO-US14679.
XX
PR   22-JUN-1998;   98US-0102322.
PR   17-JUL-1997;   97US-0896164.
PR   10-OCT-1997;   97US-0061599.
PR   10-OCT-1997;   97US-0061765.
PR   10-OCT-1997;   97US-0948705.
PR   11-OCT-1997;   97GB-0021697.
XX
PA   (LUDW-) LUDWIG INST CANCER RES.
XX
PI   Chen Y,  Gout I,  Gure A,  O'Hare M,  Obata Y,  Old LJ;
PI   Pfreundschuh M,  Sahin U,  Scanlan MJ,  Stockert E;
PI   Tureci O;
XX
DR   WPI; 1999-132448/11.
XX
```

```
PT   New isolated cancer associated nucleic acids and polypeptides -
PT   isolated using sera from cancer patients, used to develop products
PT   for the diagnosis, monitoring or treatment of cancers
XX
PS   Claim 67; Page 481-482; 787pp; English.
XX
CC   The invention relates to a method for diagnosing a disorder characterised
CC   by expression of a human cancer associated antigen precursor coded for by
CC   a nucleic acid molecule (NAM). The method comprises: (a) contacting a
CC   biological sample isolated from a subject with an agent that specifically
CC   binds to the NAM, an expression product or a fragment of an expression
CC   product complexed with an HLA molecule; and (b) determining the
CC   interaction between the agent and the NAM or the expression product as a
CC   determination of the disorder. The products and methods can be used in
CC   the diagnosis, monitoring, research, or treatment of conditions
CC   characterised by the expression of various cancer associated antigens.
CC   The invention provides nucleic acid sequences and encoded polypeptides
CC   which are cancer associated antigen precursors expressed in human breast
CC   cancer, renal cancer, colon cancer, gastric cancer, prostate cancer and
CC   lung cancer.
XX
SQ   Sequence 1580 BP; 481 A; 352 C; 359 G; 388 T; 0 other;

  Query Match             57.6%;  Score 19.6;  DB 20;  Length 1580;
  Best Local Similarity   81.5%;  Pred. No. 1.6e-02;
  Matches   22;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       3 GCCTCCGGAGGAACCGNCTGCCCATGC 29
           |||  ||||||| ||| |||| |||||
Db      99 GCCCGCGGAGGAGCCGCCTGCGCATGC 125


Search completed: March 11, 2003, 00:17:20
Job time : 158.822 secs
```